Using betahistine in the treatment of patients with Menière’s disease: a meta-analysis with the current randomized-controlled evidence

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisReviewForskningpeer review

  • Louise Devantier
  • Dan Hougaard, Aalborg University Hospital
  • ,
  • Mina Nicole Händel, Bispebjerg og Frederiksberg Hospital, The Danish Health Authority, Islands Brygge 67, 2300, Copenhagen S, Denmark.
  • ,
  • Frank Liviu-Adelin Guldfred, Ear, Nose and Throat Clinic, Faxe, Denmark.
  • ,
  • Jesper Hvass Schmidt, Syddansk Universitet, Odense University Hospital
  • ,
  • Bjarki Djurhuus, Københavns Universitet
  • ,
  • Henriette Edemann Callesen, The Danish Health Authority, Islands Brygge 67, 2300, Copenhagen S, Denmark.

Background: Betahistine is used worldwide to treat patients with Menière’s disease. However, despite it being used for decades, diverging opinions on the effect of betahistine on Menière’s symptomatology still exist. Aims: The objective of this systematic review was to provide an overview and rate the certainty of the current evidence base regarding the use of betahistine to treat patients with Menière’s disease. Materials and methods: A systematic literature search was conducted in October 2019. The search strategy was subdivided into searches for existing guidelines, systematic reviews and individual randomized controlled trials (RCT) investigating the usage of betahistine as compared to placebo, in patients with Ménière’s disease. The primary outcome was the frequency of vertigo attack(s) and occurrence of serious adverse events. Results: We identified three relevant guidelines and three systematic reviews: however, neither included any relevant trials matching our inclusion criteria. An individual search for RCTs identified one trial. The results from this particular trial showed no difference in effects on symptoms following treatment with betahistine. Conclusions and Significance: There is a need for further well-conducted placebo RCTs. Currently, there is still a lack of substantial evidence supporting betahistine as a significant and adequate treatment for patients diagnosed with Menière’s disease. Trial registration number: The protocol is registered in PROSPERO. Registration number: CRD42018110127 Accepted 11.10.2018.

OriginalsprogEngelsk
TidsskriftActa Oto-Laryngologica
Vol/bind140
Nummer10
Sider (fra-til)845-853
Antal sider9
ISSN0001-6489
DOI
StatusUdgivet - okt. 2020

Se relationer på Aarhus Universitet Citationsformater

ID: 198710305